Physician profile
Robert D Padgett
NPI 1306832910
$5,185.10
in general payments reported to CMS, 2019-2025
37 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $371 · 2021: $473 · 2022: $235 · 2023: $742 · 2024: $1,158 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,286.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $760.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $491.93 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $448.75 | 2019-2025 | |
| Amgen INC. | $360.39 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.92 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $317.30 | 2019-2024 | |
| Exact Sciences Corporation | $295.50 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $250.90 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $227.83 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $202.77 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $139.02 | 2023-2024 | Qelbree, Qelbree |
| Gilead Sciences, INC. | $130.49 | 2019-2025 | |
| Novo Nordisk INC | $123.64 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $122.65 | 2019-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $122.60 | 2021-2024 | Eliquis |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Padgett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.